title: [Expression of metalloproteinase MMP-9 and tissue inhibitor of metalloproteinase TIMP-2 in placenta of pregnant women with intrauterine growth restriction].
abstract: BACKGROUND
  The development of pregnancy depends on many factors, among other the implantation and the development of the placenta and placental vascularity The correct course of these processes depends on the proper activity of the enzymes degradating elements of extracellular matrix and basal membrane - metalloproteinases.
  
  
  OBJECTIVE
  Assessment of the expression of MMP-9 and TIMP-2 in the placenta of women with intrauterine fetal growth restriction.
  
  
  METHODS
  Two study groups were distinguished - with untreated IUGR and with IUGR treated with the acetylsalicylic acid and L-arginine and the control group with correct fetal growth and course of pregnancy Marked microscope preparations from placental samples were made with specific antibodies for MMP-9 and TIMP-2.
  
  
  RESULTS
  The greatest intensity of the reaction and the villous TIMP-2 expression was characteristic of the group with untreated IUGR. Strongest expression MMP-9 was observed in the control group. The smallest surface of the trophoblast with positive MMP-9 reaction appeared in the group with untreated IUGR.
  
  
  CONCLUSIONS
  High MMP-9 activity in the placenta correlates with its correct structure and function. Application of IUGR treatment reduces the expression of TIMP-2 in the placental villi.
authors.affiliation: Klinika Patologii Ciazy I Katedra Ginekologii i Połoznictwa Uniwersytet Medyczny w Łodzi, Polska.
authors.forename: Arkadiusz
authors.initials: A
authors.lastname: Swierczewski
authors.forename: Józef
authors.initials: J
authors.lastname: Kobos
authors.forename: Jacek
authors.initials: J
authors.lastname: Pasiński
authors.forename: Urszula
authors.initials: U
authors.lastname: Kowalska-Koprek
authors.forename: Agata
authors.initials: A
authors.lastname: Karowicz-Bilińska
mesh_terms: D000328:Adult; D001120:Arginine / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy / Q000201:enzymology*; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D010920:Placenta / Q000201:enzymology*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011247:Pregnancy / Q000378:metabolism*; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000378:metabolism*; D055815:Young Adult
chemical_list: D010975:Platelet Aggregation Inhibitors; C560823:TIMP2 protein, human; D019716:Tissue Inhibitor of Metalloproteinase-2; D001120:Arginine; D020780:Matrix Metalloproteinase 9; D001241:Aspirin